3rd World ADC Asia 2024

The year 2024 has been considered the 'coming of age' era for antibody-drug conjugates, in great part due to the remarkable resurgence in drug development across the Asia-Pacific region. This part of the world is taking the ADC industry by storm with high-profile deals, multiple approvals, multiple ADCs moving into clinical trials, and novel targets being explored just to name some advancements.

Back by popular demand after a short break, the 3rd World ADC Asia is bringing together pioneers and key opinion leaders across mega-pharma and biotechnology focusing on China, Japan, Taiwan, South Korea and Singapore. They'll be sharing their most pressing challenges, novel payloads, conjugation, and linker innovations to inform ADC development and improve targeting accuracy.

Alongside exclusive insights on the latest clinical developments taking place in the space, the many networking opportunities available will also help you build the strategic collaborations required to meet regulatory standards, understand CMC manufacturing, deal with supply chain issues, and more.

We hope you can join us at this must-attend event for the ADC Community based in the APAC region where the East will meet the West. By learning from recent innovations from the East and long-standing experts from the West, you will be able to propel your ADC development further than ever before.

URLs:
Website: https://go.evvnt.com/2191904-0?pid=10018
Tickets: https://go.evvnt.com/2191904-2?pid=10018
Brochure: https://go.evvnt.com/2191904-3?pid=10018

Prices:
Drug Developer Pricing Conference + Pre-Conference Workshop Day: USD 1972.00,
Drug Developer Pricing Conference Only: USD 1474.00,
Academic Pricing Conference + Pre-Conference Workshop Day: USD 1772.00,
Academic Pricing Conference Only: USD 1274.00,
Service Provider Conference + Pre-Conference Workshop Day: USD 5097.00,
Service Provider Conference Only: USD 3699.00

Speakers: Dohyun Nam, Chairman, Professor, Aimed Bio Inc., Jinwon Jung, Senior Directory, ABL Bio, Jia He, Senior Research Analyst Targeted Therapies, Beacon, Shanshan Xu, Vice President, External Innovations, BioNTech, Mingjiu Chen, Chief Executive Officer, Biosion, Ziping Wei, Chief Executive Officer, Bliss Biopharma, Dhiraj Gambhire, Executive Director, Global Clinical Development, Daiichi Sankyo, Yasuyuki Kaneta, Senior Director, Daiichi Sankyo, Masayuki Miyano, Principal Scientist, Eisai, Mike Liao, Global Clinical Pharmacaology Lead - Oncology, Genentech, Paul Song, Chief Scientific Officer, Genequantum Healthcare, Amy Que, Chief Technology Officer, Genequantum Healthcare, Jun Ge, Executive Director, Head of China Clinical Development, Gilead, Shan Yongqian, General Manager, Global Innovation Center, Henlius Biotech, Ben Ayers, Vice President, AntibodyDrug Conjugates, Hummingbird Bioscience, Gary Khoo, Vice President CMC, Hummingbird Bioscience, Tse Wen, Chang Founder and Chairman, Immunwork, Zaiqi Wang, Chief Executive Officer, Inxmed, Sun-Hwa Lee, Chief Scientific Officer, Novelty Nobility, Heidi Wang, Chief Executive Officer, OBI Pharma, James Palacino, Senior Vice President and Head of Research, Orum Therapeutics, Vivian Trang, Principal Scientist, Pfizer, Hyun Yong Cho, Chief Scientific Officer, PinotBio, Amy Han, Executive Director, Regeneron Pharmaceuticals, Nitin Damle, Executive Vice President and Chief Innovation Officer, Sun Pharma Advanced Research Company , Mary Chaohong Hu, Chief Executive Officer, Shanghai Miracogen/ Lepu Biopharma, Shumin (Sam) Liu, Chief Executive Officer, Shenzhen Enduring Biotech, Hsing-Mao Chu, Chief Executive Officer, T-E Meds, Steven Kan, Chief Executive Officer, Thousand Oaks Biologics, Jangsoon Lee, Associate Professor, Director Preclinical Core, University of Hawaii Cancer Center, Seung-Jae Myung, Professor of Medicine, University of Ulsan Asan Medical Center